Credits 34RF.com A study published in the review American Journal of Psychiatry
has just demonstrated the possible effectiveness of ketamine used as an infusion in the treatment of alcoholism.
According to Celia Morgan, head of trials Ketamine for reduction of Alcohol Relapse (KARE), no new treatment for alcoholism has been developed in the last five decades. She added that the discovery of this treatment with ketamine in low doses combined with therapeutic treatment could give new hope to alcoholics and save lives.
Researchers from the University of Exeter and the American biotechnology company Awakn Life Sciences even claimed that people who received ketamine infusions accompanied of therapies were 2.7 times less likely to relapse compared to people who received placebo and accompanying therapy.
The effects of ketamine Ketamine, qualified as an essential medicine by the WHO, is an anesthetic used during surgery and to relieve pain.
May also cause effects such as hallucination or changes in perception, it can be used to treat certain s mental disorders characterized by rigid behavior including addiction.
According to Morgan, also a professor of psychopharmacology at the University of Exeter, the use of ketamine produced positive effects six months after administration of three infusions for three weeks, accompanied by a final therapy or education session in the fourth week.
Despite the positive results from ketamine treatment, Morgan said the treatment may not work for everyone. world. Indeed, the effects may be decisive in some while this will not be the case in others. We will still have to see if we will need additional sessions after the 4 weeks of treatment.
For To demonstrate the viability of the treatment, determining its long-term effects is crucial, as indicated by Allan Young, director of the Center for the Treatment of Affective Disorders at King’s College London, who was not involved in the study.
In any case, this is an important discovery that could allow better handling of cases of alcohol addiction.